Form D · Biotechnology
Astrin Biosciences, Inc.
Saint Paul, MN · CIK 0002025644
Offering snapshot reported Jun 11, 2024 · SEC filing
- Reported sold
- $22.9M Offering amount: $22.9M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 31, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 11, 2024 | Initial | $22,948,872 | No comparison | 21 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-515715
Source: Form D, filed Jun 11, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robbie Horwitz | Director |
| Jayant Parthasarathy | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1000 Westgate Dr, Ste 1009
Saint Paul, MN, 55114
Saint Paul, MN, 55114